The drugmaker’s stock, along with the Dow Jones industrial average, soared on the report that eight participants who received low and medium doses of Moderna’s vaccine had blood levels of virus-fighting antibodies that were similar or greater than those in recovered COVID-19 patients. That implies but doesn’t prove, that it triggers some level of immunity.
This comes following Moncef Slaoui, one of its directors, stepped down from the board to join as a chief scientist at a White House initiative to speed up vaccine development.
Also Read: Trump Responds To Criticism, Says Obama Was “Grossly Incompetent”
Countries and companies all over the world are rushing to create a COVID-19 vaccine and taking on financial risk to making doses in large quantities before they even know if the products are safe and effective. The United States is intending to have hundreds of millions of doses of a vaccine broadly accessible by the end of the year.
213 countries or territories have been affected by the highly contagious virus.
Globally, the total number of COVID-19 cases topped 4,800,000 while the death toll crossed 318,000, as per the latest data from Johns Hopkins University.
The United States has entered into a grim situation as it recorded 1.3 Million cases of COVID-19, about one-third of the entire world’s caseload, as per Johns Hopkins University data.
(Input from Agencies)
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
